Diacylglycerol Kinase (DGK) regulates the equilibrium between phosphatidic acid (PA) and DAG. DAG is phorylated by DGK to produce PA. Ten mammalian DGK subtypes (-) that can be divided into five different types exist. Each subtype has its own tissue distribution. Among them, the production of DAG as a second messenger following stimulation of the T cell receptor is specifically regulated by DGK and DGK. However, in T cells, DGK is the predominant isoform. Certain DGK isoforms that are dysregulated cause DAG-activated PKC, attenuated insulin signaling, and dysregulated glucose metabolism. DGK participates in a variety of physiological processes, such as cell migration and proliferation, glucose uptake, immunity, and the development of neuronal networks.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V32186 | (5Z,2E)-CU-3 | 1815598-71-0 | (5Z,2E)-CU-3is a novel, potent and selective diacylglycerol kinase alpha (DGKalpha) inhibitorwithanIC50valueof0.6 μM, attenuating cancer cell proliferation and simultaneously enhancing immune responses including anti-cancer immunity. |
|
V73996 | AMB639752 | 371210-26-3 | AMB639752 is a potent DGKα inhibitor. |
|
V73987 | BAY 2965501 | 2732902-08-6 | BAY 2965501 is a potent and specific diacylglycerol kinase zeta (DGKζ) inhibitor. |
|
V51059 | BAY-2965501 | DGKzeta inhibitor | |
|
V74001 | BMS-332 | 2407892-15-1 | BMS-332 is a dual (bifunctional) inhibitor of DGKα/ζ lipokinase with IC50 of 0.005 μM (DGKα) and 0.001 μM (DGKζ) respectively. |
|
V73995 | BMS-496 | 2407854-31-1 | BMS-496 is a dual (bifunctional) inhibitor of DGKα/ζ lipokinase with IC50 of 0.09 μM (DGKα) and 0.006 μM (DGKζ) respectively. |
|
V73988 | BMS-502 | 2407854-18-4 | BMS-502 (Compound 22) is a potent dual (bifunctional) inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50s of 4.6 nM and 2.1 nM. |
|
V73997 | BMS-684 | 313552-29-3 | BMS-684 is a selective DGKα inhibitor (antagonist) with IC50 of 15 nM. |
|
V73999 | Cochlioquinone A (Luteoleersin) | 32450-25-2 | Cochlioquinone A is an ATP-competitive diacylglycerol kinase inhibitor (Ki= 3.1 μM). |
|
V73989 | DGK-IN-1 | 2407892-34-4 | DGK-IN-1 is a T cell activator from patent WO2020006018A1, Example 25. |
|
V74000 | DGKα&ζ-IN-1 | 2830643-06-4 | DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. |
|
V73993 | DGKα-IN-2 | 2648556-92-5 | DGKα-IN-2 (example 48) is a DGKα inhibitor (antagonist) with IC50 of 0.9 nM, found in patent WO2021105115. |
|
V73994 | DGKα-IN-3 | 2648418-86-2 | DGKα-IN-3 (example 25) is a DGKα inhibitor (antagonist) with IC50 of 283 nM, found in patent WO2021105115. |
|
V74003 | DGKα-IN-4 | 2648723-43-5 | DGKα-IN-4 (example 432) is a DGKα inhibitor (antagonist) with IC50 of 0.1 nM, found in patent WO2021105117. |
|
V74002 | DGKα-IN-6 | 2886734-91-2 | DGKα-IN-6 is a DGKα inhibitor (antagonist) with IC50 of 1.377 nM, found in patent WO2022271650 (compound 143). |
|
V73992 | DGKα-IN-7 | 2886092-50-6 | DGKα-IN-7 is a DGKα inhibitor (antagonist) with IC50 of 6.225 nM, found in patent WO2022271684 (compound 100). |
|
V73998 | DGKζ-IN-1 | 2660218-70-0 | DGK z-IN-1 (compound 9) is an inhibitor (blocker/antagonist) of DGKz. |
|
V74004 | DGKζ-IN-4 | 2778366-77-9 | DGKζ-IN-4 is a DGKζ inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
